Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Circle Internet Group Inc. Class A Common Stock (CRCL) vs Iovance Biotherapeutics Inc. Common Stock (IOVA) Price & Performance

Circle Internet Group Inc. Class A Common StockTrade
Iovance Biotherapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Circle Internet Group Inc. Class A Common Stock vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Circle Internet Group Inc. Class A Common Stock trades at $86.4 (market cap $20.52B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.8 (market cap $6.04B). The key difference: Circle Internet Group Inc. Class A Common Stock is far larger — about 3.4× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Circle Internet Group Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Circle Internet Group Inc. Class A Common Stock for 0 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.

CRCLIOVA
Market Cap
$20.52B$6.04B
Volume
9,813,61014,805,993
Sector
FinancialsHealth
52-Week High
$150.48$14.82
52-Week Low
$50.23$1.81
Typical Hold Time
0 Days0 Days
Enterprise Value
$19.03B$5.97B

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CRCL
100% Buy0% Sell
Avg holding period · 0 Days
IOVA
100% Buy0% Sell
Avg holding period · 0 Days

About Circle Internet Group Inc. Class A Common Stock

Circle Internet Group provides internet financial infrastructure centered on its stablecoin network. Its business includes stablecoins, blockchain infrastructure for developers, digital-asset services, and payment applications.

Read more on CRCL →

About Iovance Biotherapeutics Inc. Common Stock

Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.

Read more on IOVA →